Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA. PALA (1 g/m2) was given on the first day, followed on the second day with 30 g of thymidine and 150-300 mg/m2 of 5-FU given simultaneously through two iv sites. Responses were seen in two of 17 patients (12%) with colorectal adenocarcinoma. One response was complete and one was partial. The gastrointestinal tract and CNS were the sites of dose-limiting toxic effects. Myelosuppression was observed only at 5-FU doses of 250 and 300 mg/m2.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D003110:Colonic Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D012004:Rectal Neoplasms / Q000188:drug therapy; D013936:Thymidine / Q000008:administration & dosage
D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid; D005472:Fluorouracil; D013936:Thymidine